Nearly 700,000 women across the UK will take part in a groundbreaking AI breast cancer trial designed to detect the disease earlier and improve survival rates. The initiative, announced on February 4, 2025, by the Department of Health and Social Care, marks a significant step toward using artificial intelligence to enhance cancer care.
Transforming Cancer Screening with AI
The EDITH trial (Early Detection using Information Technology in Health) will operate across 30 NHS screening sites. Women already scheduled for routine mammograms will be invited to participate. AI tools will help radiologists detect subtle changes in breast tissue, allowing for faster referrals when cancer is suspected.
Currently, two specialists are required to review each mammogram. The new AI system will allow one specialist to complete the same process safely, freeing hundreds of radiologists to treat more patients. If successful, the trial could be rolled out nationwide, cutting waiting times and saving more lives.
Government Backing and Funding
Backed by £11 million from the National Institute for Health and Care Research (NIHR), the trial is part of the UK government’s 10 Year Health Plan to modernize the NHS. The plan aims to shift healthcare from analogue to digital, reducing delays and improving patient care.
Breast cancer is the most common cancer in UK women, with around 55,000 diagnoses each year. Current screening programs prevent an estimated 1,300 deaths annually. Officials hope AI can help improve those numbers further.
Stay Ahead With Proactive Health Screening
AI is transforming early detection—pair it with timely, confidential lab tests for peace of mind. Fast results and no waiting rooms—take control of your health today.
Explore Health TestsExpert Support and Public Involvement
Health Secretary Wes Streeting, himself a cancer survivor, emphasized the urgency of improving early detection. “With record numbers diagnosed, urgent action is needed to save lives,” he said.
Professor Lucy Chappell, NIHR Chief Executive, called the project “a significant step forward” that could provide women with “faster, more accurate diagnoses when it matters most.”
The launch coincided with a public call for evidence to shape a new national cancer plan. Citizens, medical staff, and experts can contribute ideas via the Change NHS platform.
Looking Ahead
The trial’s results will inform future screening guidelines. If adopted, the technology could help the NHS meet new cancer treatment targets announced by NHS England. By March 2026, the goal is for 80% of patients to receive a diagnosis or the all-clear within 28 days of referral, up from the current 77% target.
Macmillan Cancer Support CEO Gemma Peters said the initiative could “spark a revolution in cancer care” if combined with equal access for all patients. Cancer Research UK Chief Executive Michelle Mitchell welcomed the move, noting that “countries with dedicated cancer plans see greater improvements in survival.”
As the trial begins, the UK positions itself as a global leader in integrating AI into public healthcare, with the potential to save thousands of lives through earlier detection and more efficient treatment.
Disclosure: We may earn a commission when you make a purchase through the ads.